[Effect of polypeptide factors of the thymus, pineal gland, bone marrow and anterior hypothalamus on the realization of transplacental carcinogenesis].
Bespalov. V G VG; Aleksandrov. V A VA; Anisimov. V N VN; Morozov. V G VG; Khavinson. V Kh VKh
Key Findings
- Thymus‑derived (FT) and pineal‑derived (FP) peptide factors lowered tumor incidence and increased latency in rats exposed to a carcinogen transplacentally
- The protective effect was seen mainly for tumors of the spinal cord, kidneys, and peripheral nervous system, not for brain tumors
- Bone‑marrow (FBM) and anterior hypothalamus (FAH) peptide factors showed no significant impact on cancer development
Practical Outcomes
- The results are from an animal model and do not provide direct, actionable protocols for humans. While they hint that thymalin might have anti‑cancer properties, more human‑focused research is needed before it can be recommended for longevity, metabolic health, or performance regimens.
Summary
In a rat study, giving a low‑molecular peptide from the thymus (similar to thymalin) after birth reduced the number and delayed the appearance of certain cancers caused by a chemical exposure before birth.
Abstract
The postnatal action of low-molecular polypeptide factors of thymus (FT), pineal gland (FP), bone marrow (FRM) and anterior hypothalamus (FAH) on transplacental carcinogenic effect of N-nitroso-N-ethylurea in rats was studied. Both FT and FP administrations decreased incidence and multiplicity of tumours and prolonged their mean latent periods. These drugs inhibited mainly the development of tumours of the spinal cord, kidneys and peripheral nervous system but not those of the brain. Both FBM and FAH had no significant influence on transplacental carcinogenesis. FT and FP anticarcinogenic effect is supposed to be due to their normalizing action on hormonal metabolic and immunological shifts arising in the body after transplacental administration of the carcinogen.
Study Information
pubmed
1984